ICON's Leadership and Performance in Phase 1 Clinical Trials Recognised in Independent Industry Benchmarking Report
The report, based on extensive feedback from 159 industry professionals, underscored ICON's dominance across a wide range of performance metrics and highlights the company's unwavering commitment to innovation, operational excellence, and customer satisfaction.
Key highlights from the report include:
Sponsor satisfaction: For phase 1 research, ICON outperformed all other large CROs claiming the highest overall sponsor satisfaction score of 7.4 on a scale of 1-10.
Outstanding operational metrics: ICON outperformed the average performance score of other large CROs in all 17 operational metrics, with a considerable lead differential in 14. These metrics are grouped into three categories of critical service capabilities including delivery metrics (such as adhering to project timelines), staff characteristics (like therapeutic expertise), and accessibility metrics (clinic availability, for example).
Robust brand strength: Across the four brand strength performance metrics of familiarity, leadership, reported recent use, and preference, ICON was the only large CRO to improve its scores across the board compared to ISR's 2024 iteration of this research, with the largest gains in leadership and preference.
Consistency of excellence: For six consecutive years, ICON has outperformed the weighted average performance scores of the other large CROs in phase 1 clinical trials, demonstrating sustained excellence and reliability.
'ICON's strong results in this report reflect the dedication, expertise, and innovation that drive our teams globally,' said Steve Cutler, CEO. 'Our consistent leadership in phase 1 clinical trials is a testament to our ability to meet and exceed client expectations, deliver high-quality outcomes, and advance breakthroughs in early-phase development.'
The benchmarking report used a rigorous methodology to ensure results reflected ICON's true impact and performance in the competitive phase 1 landscape. ISR screened participants to ensure relevance of role and responsibility, and mandated a recent interaction with a CRO. The survey data was collected in Q4 2024.
For more information, please visit www.iconplc.com/earlyclinical
About ICON plc
ICON plc is a world-leading clinical research organisation powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,250 employees in 97 locations in 55 countries as at March 31, 2025. For further information about ICON, visit: www.iconplc.com.
About ISR Market Research:
ISR utilises primary research methodologies to offer novel insights into the drug development industry. As an independent market research partner focusing on the life sciences space, ISR helps clients make data-informed decisions with specificity and precision that generalist firms can't match. ISR's analysts are industry experts in their own right with over 15 years of experience in this niche. They also diligently curate membership for ISR's Life Science Panel of respondents. Panel members are from a wide spectrum of geographies and job levels across a variety of roles & responsibilities, and their valuable experiential data informs both ISR's off-the-shelf syndicated reports and robust custom research capabilities.
https://isrreports.com/
https://www.linkedin.com/company/isrreports
ICON/ICLR-G
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Earnings To Watch: EverQuote (EVER) Reports Q2 Results Tomorrow
Online insurance comparison site EverQuote (NASDAQ:EVER) will be reporting earnings this Monday afternoon. Here's what investors should know. EverQuote beat analysts' revenue expectations by 5.2% last quarter, reporting revenues of $166.6 million, up 83% year on year. It was an exceptional quarter for the company, with EBITDA guidance for next quarter exceeding analysts' expectations and an impressive beat of analysts' EBITDA estimates. Is EverQuote a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting EverQuote's revenue to grow 33.9% year on year to $156.9 million, slowing from the 72.3% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.51 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. EverQuote has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 7.8% on average. Looking at EverQuote's peers in the online marketplace segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Shutterstock delivered year-on-year revenue growth of 21.3%, beating analysts' expectations by 7.5%, and eBay reported revenues up 6.1%, topping estimates by 3.1%. Shutterstock's stock price was unchanged after the resultswhile eBay was up 18.5%. Read our full analysis of Shutterstock's results here and eBay's results here. Investors in the online marketplace segment have had steady hands going into earnings, with share prices flat over the last month. EverQuote is up 2.3% during the same time and is heading into earnings with an average analyst price target of $34.17 (compared to the current share price of $25.30). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
an hour ago
- Yahoo
Why Casella Waste Systems Stock Flopped on Friday
Key Points The company's bottom-line miss in its second quarter was striking. That was compounded by a guidance reduction for full-year profitability. 10 stocks we like better than Casella Waste Systems › Solid waste and recycling management company Casella Waste Systems (NASDAQ: CWST) was surely eager to start its weekend. On Friday, the company published quarterly results that were a dud with investors, who sent its share price down by more than 5%. That was more deeply in the red than the S&P 500 index's 1.6% dive. One big whiff Much of this was because of a fairly wide bottom-line miss in Casella's second quarter, the results of which were published after market close Thursday. In the quarter, Casella booked revenue of over $465 million. So far, so good, as this was more than 23% higher than in the same quarter of 2024. Further down the profit and loss statement, however, the company revealed that its generally accepted accounting principles (GAAP) net income fell to $5.2 million ($0.08 per share) from the year-ago profit of slightly over $7 million. That drop was discouraging enough, but it was exacerbated by the fact that analysts were expecting far better from the company. On average, they were modeling $0.33 per share for bottom-line profitability, although they underestimated revenue with a collective $454 million projection. Acquisitions played a role in Casella's top-line growth, as the company completed six buyouts across the first half of this year. Management also said higher landfill volumes were a catalyst. Notable guidance revisions Outside of the bottom-line miss, Casella's change in guidance was dismaying for investors. Although it raised its outlook for full-year 2025 revenue -- $1.82 billion to $1.84 billion from just under $1.78 billion to a bit over $1.8 billion -- it cut that for profitability. The company now believes its GAAP net income will land at $8 million to $18 million; the previous guidance called for $10 million to $25 million. Should you buy stock in Casella Waste Systems right now? Before you buy stock in Casella Waste Systems, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Casella Waste Systems wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Casella Waste Systems Stock Flopped on Friday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Addus HomeCare (ADUS) Q2 Earnings: What To Expect
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting results this Monday afternoon. Here's what you need to know. Addus HomeCare missed analysts' revenue expectations by 0.6% last quarter, reporting revenues of $337.7 million, up 20.3% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' sales volume estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Addus HomeCare's revenue to grow 20.8% year on year to $346.5 million, improving from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.46 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street's revenue estimates three times over the last two years. Looking at Addus HomeCare's peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 15.3%, beating analysts' expectations by 5.2%, and Option Care Health reported revenues up 15.4%, topping estimates by 4.6%. Option Care Health traded down 2.7% following the results. Read our full analysis of BrightSpring Health Services's results here and Option Care Health's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the senior health, home health & hospice stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Addus HomeCare is down 5.3% during the same time and is heading into earnings with an average analyst price target of $136.45 (compared to the current share price of $104.74). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
